

Sarah P Psutka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4410363/publications.pdf>

Version: 2024-02-01

92
papers

2,589
citations

257101

24
h-index

205818

48
g-index

92
all docs

92
docs citations

92
times ranked

3424
citing authors

#	ARTICLE	IF	CITATIONS
1	Applicant perceptions of virtual interviews for society of urologic oncology fellowships during the COVID-19 pandemic. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, 41, 65-68.	0.8	7
2	Prehabilitation Exercise Before Urologic Cancer Surgery: A Systematic and Interdisciplinary Review. <i>European Urology</i> , 2022, 81, 157-167.	0.9	41
3	A Prospective Study of a Resorbable Intravesical Fiducial Marker for Bladder Cancer Radiation Therapy. <i>Advances in Radiation Oncology</i> , 2022, 7, 100858.	0.6	3
4	A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. <i>European Urology</i> , 2022, 81, 576-585.	0.9	21
5	Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis. <i>European Urology</i> , 2022, 81, 414-425.	0.9	40
6	Gene network profiling in muscle-invasive bladder cancer: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 197.e11-197.e23.	0.8	2
7	Muscle Mass Matters in Patients with Renal Cell Carcinoma, but That Is Only the Beginning. <i>Annals of Surgical Oncology</i> , 2022, 29, 2152-2154.	0.7	3
8	Magnetic resonance imaging vs. computed tomography image concordance for linear measurements and the quantification of abdominal skeletal muscle. <i>JCSM Clinical Reports</i> , 2022, 7, 24-29.	0.5	2
9	Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma. <i>Cancer Medicine</i> , 2022, 11, 3106-3114.	1.3	10
10	Sarcopenia and systemic inflammation are associated with decreased survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Cancer</i> , 2022, 128, 2073-2084.	2.0	6
11	Neoadjuvant systemic therapy in patients undergoing nephroureterectomy for urothelial cancer: a multidisciplinary systematic review and critical analysis. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	1.3	12
12	Redefining the Gender Gap in Urology Authorship: An 18-Year Publication Analysis. <i>European Urology Focus</i> , 2022, 8, 1512-1519.	1.6	7
13	EDITORIAL COMMENT. <i>Urology</i> , 2022, 162, 103-104.	0.5	0
14	Gender Disparities Among Editorial Boards of International Urology Journals. <i>European Urology Focus</i> , 2022, 8, 1840-1846.	1.6	10
15	A Decade of Robotic-Assisted Radical Nephrectomy with Inferior Vena Cava Thrombectomy: A Systematic Review and Meta-Analysis of Perioperative Outcomes. <i>Journal of Urology</i> , 2022, 208, 542-560.	0.2	11
16	Predictive Risk Factors for Continued Smoking after the Diagnosis of a Genitourinary Malignancy. <i>Urology</i> , 2021, 147, 178-185.	0.5	0
17	Women in Leadership in Urology: The Case for Increasing Diversity and Equity. <i>Urology</i> , 2021, 150, 16-24.	0.5	22
18	Female Authorship Trends in Urology During the COVID-19 Pandemic. <i>European Urology</i> , 2021, 79, 322-324.	0.9	5

#	ARTICLE	IF	CITATIONS
19	Prostate cancer presentation, treatment selection, and outcomes among men with HIV/AIDS: A clinical stage, race, and age-matched contemporary analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 73.e19-73.e25.	0.8	5
20	Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 144-154.	0.9	13
21	The association between sarcopenia and bladder cancer-specific mortality and all-cause mortality after radical cystectomy: A systematic review and meta-analysis. <i>Arab Journal of Urology Arab Association of Urology</i> , 2021, 19, 98-103.	0.7	12
22	Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma. <i>Cancer</i> , 2021, 127, 1974-1983.	2.0	26
23	Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos. <i>Journal of Visualized Experiments</i> , 2021, , .	0.2	11
24	Advances in the Characterization of Clear Cell Papillary Renal Cell Carcinoma: Identifying the Sheep in Wolf's Clothing. <i>European Urology</i> , 2021, 79, 478-479.	0.9	2
25	Assessing Contemporary Trends in Female Speakership within Urologic Oncology. <i>Urology</i> , 2021, 150, 41-46.	0.5	11
26	Financial Toxicity Among Patients with Prostate, Bladder, and Kidney Cancer: A Systematic Review and Call to Action. <i>European Urology Oncology</i> , 2021, 4, 396-404.	2.6	30
27	Machine Learning in Body Composition Analysis. <i>European Urology Focus</i> , 2021, 7, 713-716.	1.6	9
28	Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 496.e1-496.e8.	0.8	1
29	Research highlights of the 2020 society of urologic oncology young urologic oncologists' program. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 452-454.	0.8	0
30	A 25-year perspective on advances in the study of the epidemiology, disparities, and outcomes of urologic cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 595-601.	0.8	1
31	Reply to Kenta Ushida, Miho Shimizu, and Ryo Momosaki's Letter to the Editor re: Logan G. Briggs, Chanan Reitblat, Paul A. Bain, et al. Prehabilitation Exercise Before Urologic Cancer Surgery: A Systematic and Interdisciplinary Review. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2021.05.015 . Strategies for Effective Prehabilitation in Urologic Cancer. <i>European Urology</i> , 2021, 80, e141-e142.	0.9	0
32	The European Urology Commitment to Gender Equity and Diversity: Expanding Cognitive Diversity through Inclusivity at the Podium. <i>European Urology</i> , 2021, 80, 450-453.	0.9	11
33	Metastasectomy in kidney cancer: current indications and treatment approaches. <i>Current Opinion in Supportive and Palliative Care</i> , 2021, 15, 266-275.	0.5	4
34	Overdiagnosis and Lives Saved by Reflex Testing Men With Intermediate Prostate-Specific Antigen Levels. <i>Journal of the National Cancer Institute</i> , 2020, 112, 384-390.	3.0	10
35	Plasmacytoid Urothelial Carcinoma: Response to Chemotherapy and Oncologic Outcomes. <i>Bladder Cancer</i> , 2020, 6, 71-81.	0.2	16
36	Introduction: Personalizing risk stratification in bladder cancer: Moving away from "the eyeball test" and embracing objective quantification of risk. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 695-697.	0.8	1

#	ARTICLE	IF	CITATIONS
37	Quantification of body composition in renal cell carcinoma patients: Comparing computed tomography and magnetic resonance imaging measurements. <i>European Journal of Radiology</i> , 2020, 132, 109307.	1.2	11
38	Personalizing preoperative risk stratification and refining patient selection for cytoreductive nephrectomy in metastatic renal cell carcinoma. <i>Cancer</i> , 2020, 126, 3912-3915.	2.0	5
39	Xanthogranulomatous Pyelonephritis With Direct Extension Into the Liver. <i>American Journal of Medicine</i> , 2020, 133, 1054-1055.	0.6	6
40	Risk stratification metrics for bladder cancer: Comprehensive Geriatric Assessments. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 725-733.	0.8	13
41	Efficacy of Upfront Docetaxel With Androgen Deprivation Therapy for Castration-Sensitive Metastatic Prostate Cancer Among Minority Patients. <i>American Journal of Therapeutics</i> , 2020, Publish Ahead of Print, e380-e387.	0.5	2
42	Reassessing the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in 2019. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 276-283.	1.8	11
43	Bladder Cancer Multidisciplinary Clinic (BCMC) Model Influences Disease Assessment and Impacts Treatment Recommendations. <i>Bladder Cancer</i> , 2019, 5, 289-298.	0.2	7
44	MRI quantitation of abdominal skeletal muscle correlates with CT-based analysis: implications for sarcopenia measurement. <i>Applied Physiology, Nutrition and Metabolism</i> , 2019, 44, 814-819.	0.9	33
45	Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication. <i>Journal of Urology</i> , 2019, 202, 936-943.	0.2	14
46	Reply by Authors. <i>Journal of Urology</i> , 2019, 202, 943-943.	0.2	0
47	Role of metastasis-directed treatment in kidney cancer. <i>Cancer</i> , 2018, 124, 3641-3655.	2.0	38
48	Usefulness of Preoperative Ultrasound for the Evaluation of Testicular Rupture in the Setting of Scrotal Gunshot Wounds. <i>Journal of Urology</i> , 2018, 199, 1546-1551.	0.2	4
49	Unraveling Associations Between Occupation and Bladder Cancer Aggressiveness: Describing the Landscape. <i>European Urology Focus</i> , 2018, 4, 731-732.	1.6	0
50	Staging the Host: Personalizing Risk Assessment for Radical Cystectomy Patients. <i>European Urology Oncology</i> , 2018, 1, 292-304.	2.6	54
51	Nutritional Predictors of Perioperative Complications and Mortality Following Nephrectomy for Renal Malignancies: A Population-Based Analysis. <i>Kidney Cancer</i> , 2018, 2, 147-174.	0.2	2
52	Heterogeneity of risk within Gleason 4+4, 4+5 and 5+4 prostate cancer. <i>Scandinavian Journal of Urology</i> , 2018, 52, 340-348.	0.6	6
53	Changes in Lean Muscle Mass Associated with Neoadjuvant Platinum-Based Chemotherapy in Patients with Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2018, 4, 411-418.	0.2	18
54	Prostate cancer presentation, treatment selection, and outcomes among men with HIV/AIDS: A clinical, stage, and age-matched analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 245-245.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Real world outcomes of upfront docetaxel for hormone naïve metastatic prostate cancer in an ethnically diverse inner-city population.. Journal of Clinical Oncology, 2018, 36, 359-359.	0.8	16
56	Upfront docetaxel for castration-sensitive metastatic prostate cancer in an ethnically diverse inner-city population.. Journal of Clinical Oncology, 2018, 36, e17038-e17038.	0.8	0
57	Validation study of a new semi-automated software program for CT body composition analysis. Abdominal Radiology, 2017, 42, 2369-2375.	1.0	42
58	Association of race and margin status among patients undergoing robotic partial nephrectomy for T1 renal cell carcinoma: Results from a population-based cohort. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 662.e17-662.e21.	0.8	13
59	Urology Residents' Experience and Attitude Toward Surgical Simulation: Presenting our 4-Year Experience With a Multi-institutional, Multi-modality Simulation Model. Urology, 2017, 109, 32-37.	0.5	8
60	Renal fossa recurrence after nephrectomy for renal cell carcinoma: prognostic features and oncological outcomes. BJU International, 2017, 119, 116-127.	1.3	33
61	Complications and Outcomes Associated With Surgical Management of Renal Cell Carcinoma Involving the Liver: A Matched Cohort Study. Urology, 2017, 99, 155-161.	0.5	17
62	Patient-reported Functional Outcomes Following Open, Laparoscopic, and Robotic Assisted Radical Prostatectomy Performed by High-volume Surgeons at High-volume Hospitals. European Urology Focus, 2016, 2, 172-179.	1.6	25
63	Concordance of Pathologic Features Between Metastatic Sites and the Primary Tumor in Surgically Resected Metastatic Renal Cell Carcinoma. Urology, 2016, 96, 106-113.	0.5	9
64	Urethral Foreign Bodies: Clinical Presentation and Management. Urology, 2016, 97, 257-260.	0.5	45
65	Use of Personalized Printed 3-Dimensional Kidney Models for Simulation before Nephron Sparing Surgery: Methodology and Examples from a Case Series. Urology Practice, 2016, 3, 124-133.	0.2	2
66	Decreased Skeletal Muscle Mass is Associated with an Increased Risk of Mortality after Radical Nephrectomy for Localized Renal Cell Cancer. Journal of Urology, 2016, 195, 270-276.	0.2	104
67	Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy—What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression?. Journal of Urology, 2016, 195, 1754-1759.	0.2	46
68	Clinical and radiographic predictors of the need for inferior vena cava resection during nephrectomy for patients with renal cell carcinoma and caval tumour thrombus. BJU International, 2015, 116, 388-396.	1.3	66
69	Management of inferior vena cava tumor thrombus in locally advanced renal cell carcinoma. Therapeutic Advances in Urology, 2015, 7, 216-229.	0.9	106
70	Oncologic Surveillance After Surgical Resection for Renal Cell Carcinoma: A Novel Risk-Based Approach. Journal of Clinical Oncology, 2015, 33, 4151-4157.	0.8	73
71	Comparison of Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. European Urology, 2015, 67, 252-259.	0.9	329
72	The Impact of Targeted Therapy on Management of Metastatic Renal Cell Carcinoma: Trends in Systemic Therapy and Cytoreductive Nephrectomy Utilization. Urology, 2015, 85, 442-451.	0.5	35

#	ARTICLE	IF	CITATIONS
73	Mortality after Radical Cystectomy: Impact of Obesity Versus Adiposity after Adjusting for Skeletal Muscle Wasting. <i>Journal of Urology</i> , 2015, 193, 1507-1513.	0.2	60
74	The association of statin therapy with clinicopathologic outcomes and survival among patients with localized renal cell carcinoma undergoing nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 388.e11-388.e18.	0.8	16
75	Evaluation of current surveillance guidelines following radical cystectomy and proposal of a novel risk-based approach. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 339.e1-339.e8.	0.8	21
76	Risk Stratification in Hormone-sensitive Metastatic Prostate Cancer: More Questions than Answers. <i>European Urology</i> , 2015, 68, 205-206.	0.9	7
77	The association between metformin use and oncologic outcomes among surgically treated diabetic patients with localized renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 67.e15-67.e23.	0.8	23
78	Sarcopenia in patients with bladder cancer undergoing radical cystectomy: Impact on cancer-specific and all-cause mortality. <i>Cancer</i> , 2014, 120, 2910-2918.	2.0	242
79	Diabetes Mellitus is Independently Associated with an Increased Risk of Mortality in Patients with Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 192, 1620-1627.	0.2	33
80	Out-of-pockets costs for patients receiving targeted agents for metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15598-e15598.	0.8	2
81	AUA and NCCN surveillance guidelines for RCC: Do they effectively capture recurrences following nephrectomy?. <i>Journal of Clinical Oncology</i> , 2014, 32, 402-402.	0.8	8
82	EAU and NCCN surveillance guidelines for bladder cancer: Do they effectively capture recurrences following cystectomy?. <i>Journal of Clinical Oncology</i> , 2014, 32, 310-310.	0.8	0
83	Diabetes mellitus and risk of cancer-specific mortality among patients with clear cell renal cell carcinoma undergoing nephrectomy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 516-516.	0.8	1
84	Long-Term Oncologic Outcomes After Radiofrequency Ablation for T1 Renal Cell Carcinoma. <i>European Urology</i> , 2013, 63, 486-492.	0.9	274
85	Uncertainty and perception of danger among patients undergoing treatment for prostate cancer. <i>BJU International</i> , 2013, 111, E84-91.	1.3	23
86	Bladder diverticula in children. <i>Journal of Pediatric Urology</i> , 2013, 9, 129-138.	0.6	34
87	Psychosocial aspects of active surveillance. <i>Current Opinion in Urology</i> , 2013, 23, 273-277.	0.9	33
88	Long-term durable oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 384-384.	0.8	3
89	Pathologic down-staging and complete pathologic response with gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder.. <i>Journal of Clinical Oncology</i> , 2012, 30, 307-307.	0.8	0
90	Men With Organ-confined Prostate Cancer and Positive Surgical Margins Develop Biochemical Failure at a Similar Rate to Men With Extracapsular Extension. <i>Urology</i> , 2011, 78, 121-125.	0.5	27

#	ARTICLE	IF	CITATIONS
91	Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. Journal of Clinical Investigation, 2008, 118, 2592-9.	3.9	224
92	Naloxegol versus Alvimopan for Enhancing Postoperative Recovery following Radical Cystectomy for Bladder Cancer. Urology Practice, 0, , .	0.2	0